Piramal Pharma Limited — Important, 18-02-2025: General Updates

The US FDA recently conducted a General GMP inspection at Piramal Pharma's Turbhe facility, leading to the issuance of a Form-483 with six observations. The observations focus on enhancing procedures and practices, with no concerns related to data integrity. Piramal Pharma is preparing a comprehensive response to these observations, which will be submitted within the required timeframe. The company's commitment to upholding the highest standards of compliance remains strong, and it expresses confidence in effectively addressing the identified issues. Investors should monitor the situation closely, as this reflects the company’s dedication to maintaining operational integrity.